In this episode of Data in Biotech, Ross Katz sits down with Dave Johnson, CEO and co-founder of Dash Bio, a next-gen drug development services company with a mission to revolutionize clinical bioanalysis and streamline drug development.

Dave begins the episode by taking us back to the early research days in Moderna, where he helped lay the groundwork for mRNA technology, which later enabled the development of a vaccine for COVID-19 at unprecedented speed. As he explains, this automated work and pre-built systems ultimately played a central role in responding to urgent health challenges.

He also shares his firsthand experience of working in a rapidly scaling pharma company, discussing the potential challenges that arose along the way and the lessons he learned to overcome them.

Dave then proceeds to highlight the most significant insufficiencies in drug development—particularly the lack of industrialization and standardization. He explains how Dash Bio aims to address these issues, focusing on clinical bioanalysis now and expanding to broader standardization later. The goal is ultimately to develop a more efficient, high-quality end-to-end system and improve the overall efficacy of the drug development process.

Finally, Dave and Ross discuss the misconceptions surrounding lab automation and emphasize the need for a shift of perspective within the drug development space. They also touch upon Dave’s vision for the future of Dash Bio, plus his advice for aspiring biotech data leaders eager to contribute to industry transformation. 

Data in Biotech is a fortnightly podcast exploring how companies leverage data innovation in the life sciences.

Chapter Markers:

[1:38] Introduction to Dave Johnson and his career journey from Moderna to founding a next-gen drug development company

[2:57] Establishing mRNA technology groundwork in Moderna

[4:36] The challenges of scaling up COVID-19 vaccine development

[7:55] How rapid company growth impacts the organizational structure and engaging models

[11:03] The role of AI, automation, and machine learning in drug development

[12:45] Addressing the most significant insufficiencies in drug development and potential solutions

[16:31] The need for standardization and automation in drug development

[18:04] Current focus of Dash Bio on clinical bioanalysis

[19:37] The misconceptions surrounding lab automation and the need for a shift of perspective within the drug development space

[22:33] Dave’s vision for the future of Dash Bio and streamlining drug development

[25:16] The current state of lab automation

[27:41] The role of experimentation in Dash Bio's approach

[29:47] Advice for aspiring data scientists and leaders in the biotech sector

Useful Links

Dave Johnson LinkedIn

Dash Bio Website